Guides for modern genetic & molecular labs.
Practical writing on LIS vs LIMS, pharmacogenomics reporting, genetic and molecular lab software, billing and RCM, and interoperability — from the team building Labrynix.
LIS vs LIMS: What's the Difference (and Why Genetic Labs Need Both)
A LIS is patient-centric, a LIMS is sample-centric — but genetic and molecular labs need both. Here's the real difference, where they overlap, and how to choose.
Read article →PharmacogenomicsWhat Is Pharmacogenomics (PGx) Testing? A Lab's Guide
Star alleles, diplotypes, metabolizer status, CPIC guidelines — the concepts behind a pharmacogenomics report, explained for lab teams.
Read article →Buyer's GuideBest Pharmacogenomics (PGx) Reporting Software in 2026
What separates real PGx reporting software from a generic LIMS — the capabilities that matter, the tool categories, and how to evaluate them.
Read article →Buyer's GuideBest Genetic Testing Lab Software in 2026: How to Choose
The capabilities a genetic testing lab actually needs from its software — from accessioning to report to paid claim — and how to evaluate vendors.
Read article →Molecular DiagnosticsWhat Is Molecular Diagnostics? Tests, Workflows & Software
A plain-English introduction to molecular diagnostics — what it is, the core test technologies, how a sample becomes a report, and the role software plays.
Read article →InteroperabilityHL7 vs FHIR for Laboratories: A Plain-English Guide
A clear comparison of HL7 v2 and FHIR for laboratories — what each does, where ORM, ORU, and ELR fit, and why most labs need both.
Read article →Billing & RCMLaboratory Revenue Cycle Management (RCM), Explained
A practical walk-through of laboratory RCM — every stage from eligibility to payment, plus why genetic and molecular tests are uniquely hard to bill.
Read article →Buyer's GuideLIS With Built-In Billing: Why One Platform Beats Two
Why running a LIS and a separate billing system creates silos and denials — and what an honest evaluation of a unified order-to-claim platform should weigh.
Read article →LIS & LIMSWhat Is a Genetic Testing LIS? A Lab's Guide
A genetic testing LIS handles the full molecular lab journey — from order to variant or PGx report — in ways a general clinical LIS was never built for. Here's how it works.
Read article →GenomicsNGS Workflow End-to-End: From Sample to Variant Report
Follow a sample through the complete next-generation sequencing pipeline — accessioning to variant report — and see where QC, software, and qualified human review fit.
Read article →Buyer's GuideBest Molecular Diagnostics LIMS in 2026: How to Choose
A practical, vendor-fair guide to choosing a molecular diagnostics LIMS in 2026 — the capabilities that matter, and the often-overlooked gaps in billing and reporting.
Read article →ComparisonLigoLab Alternatives for Genetic & Molecular Labs
LigoLab is a strong LIS + RCM platform for pathology. If you run a genetic, molecular, or PGx lab, here's what to weigh — and the genetics-first alternative.
Read article →AI in the LabAI Agents for Genetic Labs: SOPs, Workflows & Algorithms
AI agents can draft SOPs, triage cases, route work, and flag QC issues. Here's what an 'agent' really is, where it helps, and why the human gate never moves.
Read article →ReportingHow to Build a Custom Neurology Genetic Testing Report
Neurogenetics doesn't fit a one-size template. Here's what a strong neurology genetic report includes and how AI-assisted, lab-validated report building handles the complexity.
Read article →ReportingHereditary Cancer Genetic Testing Software & Reporting
A practical buyer's guide to hereditary cancer testing software: the panel workflow, ACMG-aligned classification support, reporting, and the LIS/LIMS, billing, and integration capabilities to evaluate.
Read article →AI in the LabAI-Assisted PGx Report Drafting: Faster Sign-Out
AI can draft PGx summaries to speed sign-out without taking the decision. The genotype-to-report flow, where AI helps vs where the lab decides, and the audit trail that keeps it defensible.
Read article →Billing & RCMMolDX/DEX Z-Codes Explained: Why Molecular Claims Get Denied
A practical guide to MolDX/DEX Z-codes: what they identify, how DEX registration and the Technical Assessment work, why missing codes drive molecular denials, and how to attach the right one at order entry.
Read article →PharmacogenomicsCPIC Guidelines and CPIC-Concordant PGx Reporting: A Lab Director's Guide
CPIC guidelines tell labs how to turn a genotype into an actionable prescribing recommendation. Here is what CPIC-concordant reporting means, why FDA and CPIC sometimes disagree, and why source-cited beats opaque.
Read article →RegulatoryThe FDA LDT Rule Was Vacated: What Labs Need to Know in 2026
A federal court vacated the FDA LDT rule in March 2025 and the agency rescinded it in September. CLIA is the operative framework again. Here is what changes for labs.
Read article →PharmacogenomicsWhite-Label PGx Reporting: Add a Pharmacogenomics Line Without Replacing Your LIS
A buyer's guide to standalone, white-label pharmacogenomic reporting: keep your existing LIS, deliver via API or HL7/FHIR, brand the report as yours, and sign it out under your CLIA director.
Read article →Buyer's GuideLIS/LIMS Implementation Timeline: A Realistic Checklist for Genetic and Molecular Labs
How long does a LIS/LIMS implementation really take? A phase-by-phase timeline and checklist for genetic and molecular labs, including the integrations that drive the schedule.
Read article →Billing & RCMHow to Reduce Molecular Lab Claim Denials: A Practical Playbook
Most molecular lab denials are preventable at the front end. Here is a step-by-step playbook: capture eligibility and medical necessity up front, get CPT, Z-code, and prior auth right, generate clean claims, and close the loop with denial analytics.
Read article →ComplianceWhat Is a CLIA Lab? Certificate Types, CAP, and Compliance Software
A plain-English guide to what a CLIA lab is: the certificate types, how CLIA relates to CAP accreditation, what changed after the FDA LDT rule was vacated, and the software controls labs need.
Read article →